Registration for a live webinar on 'Innovative Vaccines and Viral Pathogenesis: Insights from Recent Monkeypox Research' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Contents
- Phase 0, I, II & III drug disposition mechanisms
- Phase I & phase II drug metabolizing enzymes
- Enzymes responsible for drug metabolism
- Effect of drug metabolism
- Importance of fraction metabolized (fm)
- 1. DMEs and drug delivery
- Cytochrome P450 gene-directed enzyme
- Cyclophosphamide
- 2. Chemotherapy resistance
- Other resistance mechanisms
- Drugs with GST mediated drug resistance
- Glucuronidation as drug resistance mechanism
- 3. Interindividual variability & precision medicine
- Variations in drug response
- Irinotecan disposition
- UGT1A1*28 allele & irinotecan-based therapy
- Genotype-based irinotecan dose findings
- Interindividual variability in UGT2B17
- UGT2B17 protein abundance is highly variable
- The UGT2B17 variability in the human liver
- fm depends on the protein abundance
- UGT2B17 and prostate cancer
- UGT2B17 and upper aero digestive tract cancer
- Other examples
- Take home messages
- Questions
Topics Covered
- Drug metabolism
- Classification of drug metabolizing enzymes (DMEs)
- Clinical significance of DMEs in cancer therapeutics
- Drug delivery
- Drug resistance
- Interindividual variability and precision oncology
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Prasad, B. (2018, June 28). Drug metabolizing enzymes in cancer therapeutics [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved November 11, 2024, from https://doi.org/10.69645/BFOZ9129.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Bhagwat Prasad has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
Other Talks in the Series: Cancer Therapies in the Personalized Medicine Era
Transcript
Please wait while the transcript is being prepared...
0:00
Hello. My name is Bhagwat Prasad and
I'm an assistant professor at the Department of Pharmaceutics,
University of Washington, Seattle WA, USA.
I'm going to talk today about drug metabolizing enzymes and cancer therapeutics.
0:17
So, content of my slides include the definition of drug metabolism;
classification of drug-metabolizing enzymes,
commonly referred as DMEs;
and clinical significance of DMEs in cancer therapeutics.
I will be mainly focusing on three parts.
First is on drug delivery to cancer cells, and drug resistance,
and interindividual variability and leveraging
interindividual variabilty in precision oncology.
0:47
Drug metabolism is a part of pharmacology in a broader sense.
If we think about pharmacology,
pharmacology is divided into two parts; pharmacokinetics and pharmacodynamics.
Pharmacokinetics is described as what body does to the drugs,
while pharmacodynamics is what drug does to the body.
In phamacokinetics, mechanistically, we can define pharmacokinetics as drug distribution.
So, when your drug is taken, it's absorbed,
it's distributed in the body,
and it's eliminated by two processes.
One is excretion from body as such,
or by chemical biotransmission of drugs called drug metabolism.
So, drug metabolism can be classified further into two categories,
Phase I drug metabolism and Phase II drug metabolism.
In Phase I drug metabolism,
a drug which is usually lipophilic is converted to
a slightly water-soluble molecule by oxidation or hydrolysis or reduction
of processes and that the hydrolyzed or
reduced or oxidized moiety is further conjugated with endogenous molecules
like gluconic acid in Phase II in drug metabolism step which gives you
a very hydrophilic metabolite that can be eliminated by a simple excretion from body.
The primary sites of drug metabolism are liver, intestine, and kidney.
For this talk, in case of cancer cells,
the cancer cells overexpresses
these drug-metabolizing enzymes so they become as a site of drug metabolism as well.
There is further complexity in drug metabolism because most of the drugs
that are being developed are substrates of drug transporters.
This is called Phase 0 drug metabolism
in this case, or drug distribution where drug is taken up by active transporters or
some kind of protein couriers that takes drugs
from the blood to a cell for example, cancer cell.
Then also, these hydrophilic moieties are excreted through the transport processes.